Efficacy and safety of everolimus plus exemestane in patients with HR+, HER2- advanced breast cancer progressing on/after prior endocrine therapy in routine clinical practice: Primary results from the non-interventional study, STEPAUT.

Guenther G Steger,Daniel Egle,Rupert Bartsch,Georg Pfeiler,Edgar Petru,Richard Greil,Ruth Helfgott,Christian Marth,Leopold Öhler,Michael Hubalek,Alois Lang,Christoph Tinchon,Ferdinand Haslbauer,Andreas Redl,Karin Hock,Mathias Hennebelle,Bernhard Mraz,Michael Gnant

The Breast（2020）

引用 12|浏览98

暂无评分

摘要

•STEPAUT, an Austrian non-interventional study, evaluated everolimus plus exemestane.•The median progression-free survival in the overall population was 9.5 months.•Majority of the patients had grade 1 (53.7%) to grade 2 (35.9%) adverse events.•Real-world data from STEPAUT were consistent with results from the BOLERO-2.

查看译文

关键词

STEPAUT,Everolimus,Hormone receptor-positive,Metastatic breast cancer,Non-interventional study,Real-world setting

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要